Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context

Abroad (travel likely)Recruiting

Conditions

Crohn Disease (CD) · Ulcerative Colitis (UC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Imelda General Hospital, Bonheiden, Belgium
Contact: Study coordinator (Peter Bossuyt, MD PhD) · peter.bossuyt@imelda.be · +3215505691

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

Inflammatory Bowel Disease (IBD) · Crohn Disease (CD) · Ulcerative Colitis (UC)

Abroad (travel likely)Recruiting

Calgary, Canada · Fredericton, Canada

IBD Biomarker Discovery and Validation Platform

Crohn Disease (CD) · Ulcerative Colitis (UC) · Inflammatory Bowel Diseases (IBD)

Abroad (travel likely)Recruiting

Guangzhou, China · Guangzhou, China

De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

Crohn Disease (CD) · Ulcerative Colitis (UC)

Abroad (travel likely)RecruitingPHASE4

Montreal, Canada

Assessing Interventions of Diet in IBD

IBD (Inflammatory Bowel Disease) · Ulcerative Colitis (UC) · Crohn Disease (CD)

Abroad (travel likely)Recruiting

Hamilton, Canada · Hamilton, Canada